To use all functions of this page, please activate cookies in your browser.
My watch list
my.bionity.com
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
7 Current news of phoremost
rss |
You can refine your search further. Select from the filter options on the left to narrow down your results. |
The two startups NeoCura and PhoreMost announce research collaboration to explore novel cancer therapeutics
19-Jan-2022
NeoCura Bio-Medical Technology Co., Ltd., a RNA-based drug research and development company in China, and PhoreMost Limited, the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’, announced an oncology drug discovery research collaboration As part of the collaboration, ...
PhoreMost and POLARISqb announce a multi-target collaboration to investigate next-generation cancer therapies
Start-ups combine biotechnology and artificial intelligence
06-Jan-2022
PhoreMost Limited, a UK-based biopharmaceutical company dedicated to developing drugs against intractable disease targets, and Polaris Quantum Biotech (POLARISqb), a NC-based quantum computing drug design company, announced a collaborationto study oncology targets currently considered ...
PhoreMost closes £33M Series B financing
Start-up is advancing its pipeline of novel therapies for oncology and diseases of ageing
25-Mar-2021
PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, announced it has completed an oversubscribed £33m ($46m) Series B investment round. The round was led by BGF, the UK’s most active growth economy investor, and included new investors ...
PhoreMost completes $15M Series-A round to enter drug discovery
Investment to fund expansion of operations and progression of drug target pipeline
22-May-2018
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has completed an £11m ($15m) Series-A investment round. The investment will be used to expand operations on the Babraham Research Campus and progress several novel drug ...
PhoreMost and Plexxikon collaborate to identify novel drug targets
16-Apr-2018
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo. Under the agreement, PhoreMost will apply its ...
PhoreMost Ltd and University of Cambridge collaborate
Identifying innovative drug targets for neurodegenerative disease
14-Oct-2016
PhoreMost Ltd (PhoreMost), a biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, has entered into a research collaboration with the laboratory of Professor David Rubinsztein at the University of Cambridge. The groups will study and translate essential cellular ...
PhoreMost Awarded £1.4M Innovate UK Funding to Develop Lead Oncology Programme
13-May-2015
PhoreMost Ltd announced that it has been selected to receive a funding award of £1.4M (approximately $2.14M USD) from the UK’s innovation agency, Innovate UK, to develop its lead oncology programme targeting mutant KRAS cancers.Based on PhoreMost’s proprietary Protein Interference technology, the ...
Page 1 From 1
